Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers help uncover drug interactions for new compound

NCT ID NCT07018635

First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 23 times

Summary

This completed phase 1 study looked at how three common drugs—an antifungal (itraconazole), an antibiotic (rifampin), and acid reducers (esomeprazole, famotidine)—change the way a new experimental drug (INCB161734) moves through the body. Sixty-three healthy adults aged 18 to 55 took part. The goal was purely to gather safety and drug-level data, not to treat any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison

    Madison, Wisconsin, 53704, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

INCB161734

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.